Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Snow days extend reviews

Executive Summary

Due to the two-day federal government shutdown, review divisions have discretion to extend any PDUFA date coming due within 30 days of the shutdown (Jan. 25 & 26) by two days. Decisions will be made on a case-by-case basis, the agency said. Texas Biotechnology's Novastan (argatroban) is one product to have its review extended: the user fee review goal for FDA's priority review of the product for use in patients with heparin-induced thrombocytopenia syndrome was originally Feb. 16 and was extended to Feb. 18

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel